Dr. Garfall on CAR T Cells in ALL – OncLive
OncLive |
Dr. Garfall on CAR T Cells in ALL
OncLive In ALL, there are 90% response rates with CAR T-cell therapy in patients who are refractory to all other therapies. However, a sizeable portion of those patients will relapse and, in most cases, those relapses will be selection for CD19-negative … |
